Ambit(美國(guó))

Ambit Biosciences

AmbitBioscienceswww.ambitbio.com生物制藥公司，致力于發(fā)現(xiàn)，開(kāi)發(fā)和商業(yè)化的藥物來(lái)治療腫瘤，自身免疫性疾病和炎癥性疾病AmbitBiosciencesisabiopharmaceuticalcompanyfocusedonthediscovery,developmentandcommercializationofdrugstotreatunmetmedicalneeds inoncology,autoimmuneandinflammatorydiseasesbyinhibitingkinasesthatareimportantdriversforthosediseases.Ourpipelinecurrentlyincludesthreeprograms,eachaimedattheinhibitionofvalidatedkinasetargets.Ourleaddrugcandidate,quizartinib,isaonce-daily,orally-administered,potentandselectiveinhibitorofFMS-liketyrosinekinase3(FLT3),avalidatedtargetinthetreatmentofAML,andiscurrentlyinPhase2bclinicaldevelopmentinrelapsed/refractoryAMLpatientswhoexpresstheFLT3-ITDmutation(FLT3-ITDpositivepatients).TheFLT3-ITDmutationactslikea“powerswitch”thatcausesleukemiccells,orblasts,tospreadmoreaggressivelyandgrowbackmorerapidlyfollowingchemotherapy,